Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
JU INSIGHT: Results from 22 Years of Followup in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial
By: Maria Franlund, MD, PhD; Marianne Mansson; Rebecka Arnsrud Godtman, MD; Gunnar Aus, MD; Erik Holmberg, PhD; Karin Stinesen Kollberg, PhD; Carl-Gustaf Pihl, MD; Johan Stranne, MD; Hans Lilja, MD; Jonas Hugosson, MD | Posted on: 01 Aug 2022
Frånlund M, Månsson M, Godtman RA et al: Results from 22 years of followup in the göteborg randomized population-based prostate cancer screening trial. J Urol 2022; 208: 292.
Study Need and Importance
Results from randomized prostate cancer screening trials are inconsistent. The aim of the present study was to present very long followup data of the Göteborg 1 screening trial which started early before opportunistic prostate specific antigen (PSA) testing was peaking and with up to 20-year duration of the screening period.
What We Found
At 22 years of followup, the prostate cancer mortality was 29% lower in the group of men who were invited every second year for PSA testing (41% in those who attended at least once) compared to a noninvited control group, but the prostate cancer incidence was 42% higher. The number of men needed to invite was 221 and the number needed to diagnose was 9 to prevent 1 prostate cancer death. Among invited men a higher prostate cancer mortality was seen among those never attending the program and among those who started the program after age 60, and the prostate cancer mortality was high 10 years after termination of the program.
Limitations
Limitations mainly include the increasing rate of opportunistic PSA testing during the study period in the control group and nonparticipation in the screening group, diluting the “true” effects of a well-organized PSA screening program.
Interpretation for Patient Care
Regular PSA testing from age 50 significantly decreases the risk of dying from prostate cancer at the expense of a rather high risk of detecting small slow-growing cancers, of which many never will need treatment. If a man chooses to participate in a prostate cancer screening program he should start around age 50. Testing should be done at least every second year and should not stop at age 70 for all men.